

Nextleaf Solutions

07:00 29 Mar 2019

Nextleaf gains as US patent granted for cannabinoid extraction from marijuana and hemp

Nextleaf Solutions Ltd (CSE:OILS) rose Thursday after announcing that the US Patent and Trade Office has granted a patent for its process of extraction, refinement and distillation of cannabinoids from marijuana and hemp.

The company said it is the first publicly traded entity to be issued an extraction patent. In addition, Nextleaf announced that it has been issued a standard patent from IP Australia, the government agency that administers intellectual property rights. The extraction process, according to Nextleaf, produces a tetrahydrocannabinol (THC) or cannabidiol (CBD) distillate that is tasteless, odorless and standardized for potency.

Shares of Nextleaf were up 7.7% to C\$0.35 in Thursday's Canadian trading.

READ: NextLeaf Solutions debuts on Canadian Securities Exchange
Nextleaf said its patented technology allows for low-quality, dried cannabis biomass to be processed into a high-purity distilled oil, simplifying the manufacturing of differentiated cannabinoid formulations and delivery methods.

Applications for the extraction process included topicals, transdermal or sublingual delivery, vape technology, edible oils, beverages and water-soluble extracts, the company said.

"Nextleaf Solutions has succeeded in beating big pharma, big tobacco, big alcohol and every single billion-dollar cannabis company to the first issued patent for the extraction and purification of cannabinoids," Nextleaf CEO Paul Pedersen said in a statement. "We believe companies that can develop and protect valuable intellectual property will benefit substantially in the long term, especially in an industry as young as the cannabis industry."

The company made its debut on the Canadian Securities Exchange earlier this month.

-Updates share prices-

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security,

Price: 0.26

Market Cap: \$28.02 m

1 Year Share Price Graph



March 2019 July 2019 November 20

Share Information

Code: OILS

Listing: CSE

52 week	High	Low
	0.83	0.26

Sector: Cannabis

Website: www.nextleafsolutions.com

Company Synopsis:

Nextleaf Solutions Ltd. ("OILS") is the first publicly traded company to be issued a U. S. patent for industrial-scale extraction and purification of cannabinoids. OILS owns a portfolio of 3 issued and 24 pending patents pertaining to the production of high-purity cannabinoid distillate, the precursor used in the manufacturing of standardized THC and CBD based products.

action@proactiveinvestors.com.au

portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nextleaf Solutions named herein, including the promotion by the Company of Nextleaf Solutions in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).